Rehmann Capital Advisory Group’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Rehmann Capital Advisory Group’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$640K	Buy	5,007 +10	+0.2%	+$1.25K	0.03%	347
2025 Q4	$609K	Buy	4,997 +2	+0%	+$229	0.03%	348
2025 Q3	$501K	Sell	4,995 -151	-3%	-$13.6K	0.03%	380
2025 Q2	$427K	Sell	5,146 -145	-3%	-$11.6K	0.03%	386
2025 Q1	$429K	Hold	5,291	–	–	0.03%	393
2024 Q4	$477K	Buy	5,291 +345	+7%	+$33.4K	0.03%	361
2024 Q3	$489K	Hold	4,946	–	–	0.03%	342
2024 Q2	$459K	Buy	4,946 +2,356	+91%	+$211K	0.03%	342
2024 Q1	$246K	Buy	+2,590	New	+$240K	0.02%	505
2021 Q4	–	Sell	-2,205	Closed	-$277K	–	591
2021 Q3	$277K	Hold	2,205	–	–	0.03%	454
2021 Q2	$299K	Buy	2,205 +280	+15%	+$36.8K	0.03%	432
2021 Q1	$261K	Buy	+1,925	New	+$288K	0.03%	441
2019 Q3	–	Sell	-929	Closed	-$81.5K	–	2157
2019 Q2	$81.5K	Sell	929 -14	-1%	-$1.19K	0.01%	677
2019 Q1	$85.3K	Sell	943 -74,454	-99%	-$6.33M	0.01%	642
2018 Q4	$2.8M	Buy	75,397 +73,962	+5,154%	+$5.96M	0.42%	30
2018 Q3	$138K	Buy	1,435 +356	+33%	+$34.5K	0.02%	500
2018 Q2	$103K	Buy	1,079 +300	+39%	+$27.6K	0.01%	558
2018 Q1	$68K	Buy	+779	New	+$71.1K	0.01%	661

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Rehmann Capital Advisory Group's XBI Position: Q1 2026 in Review

Rehmann Capital Advisory Group increased its State Street SPDR S&P Biotech ETF (XBI) stake by 0.2% in Q1 2026, buying an estimated $1.25K and bringing the position to 5,007 shares worth $640K. The position accounts for 0.03% of the portfolio, ranked #347.

Rehmann Capital Advisory Group first reported a position in XBI in Q1 2018 and has held it in 18 quarters since. The position peaked at $2.8M in Q4 2018. 814 funds tracked by Wall St. Rank hold XBI as of Q1 2026.

Rehmann Capital Advisory Group held 5,007 shares of State Street SPDR S&P Biotech ETF worth $640K as of Q1 2026.
Rehmann Capital Advisory Group bought 10 State Street SPDR S&P Biotech ETF shares in Q1 2026, an estimated $1.25K.
State Street SPDR S&P Biotech ETF made up 0.03% of Rehmann Capital Advisory Group's portfolio in Q1 2026, its #347 holding.
Rehmann Capital Advisory Group first reported a position in State Street SPDR S&P Biotech ETF in Q1 2018 and has held it in 18 quarters since.
Rehmann Capital Advisory Group's State Street SPDR S&P Biotech ETF position peaked at $2.8M in Q4 2018.
814 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q1 2026.

Based on Rehmann Capital Advisory Group's 13F filing for Q1 2026, filed 15 May 2026.